Abeona Therapeutics Inc.

1.26-0.0600-4.55%Vol 1.17M1Y Perf -58.22%
Jul 27th, 2021 14:20 DELAYED
BID1.26 ASK1.27
Open1.29 Previous Close1.32
Pre-Market1.35 After-Market-
 0.03 2.27%  - -
Target Price
4.67 
Analyst Rating
Moderate Buy 1.88
Potential %
270.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★     50.73
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap124.76M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
9.66 
Earnings Date
9th Aug 2021

Today's Price Range

1.221.30

52W Range

0.98953.79

5 Year PE Ratio Range

-9.50-2.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
4.76%
1 Month
-21.89%
3 Months
-21.43%
6 Months
-35.29%
1 Year
-58.22%
3 Years
-90.15%
5 Years
-47.41%
10 Years
-98.83%

TickerPriceChg.Chg.%
ABEO1.26-0.0600-4.55
AAPL146.54-2.4500-1.64
GOOG2 723.50-69.3900-2.48
MSFT285.08-3.9700-1.37
XOM57.73-0.7500-1.28
WFC45.140.13000.29
JNJ172.310.44000.26
FB366.47-5.9900-1.61
GE13.100.18001.39
JPM151.890.24000.16
Financial StrengthValueIndustryS&P 500US Markets
2.10
2.20
0.06
0.09
-9.60
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-471.40
-438.00
-2 180.30
-
RevenueValueIndustryS&P 500US Markets
10.00M
0.10
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.19-0.1710.53
Q04 2020-0.09-0.17-88.89
Q03 2020-0.13-0.0838.46
Q02 2020-0.17-0.1417.65
Q01 2020-0.21-0.1623.81
Q04 2019-0.29-0.30-3.45
Q03 2019-0.48-0.3527.08
Q02 2019-0.39-0.49-25.64
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.1615.79Positive
9/2021 QR-0.1710.53Positive
12/2021 FY-0.6610.81Positive
12/2022 FY-0.6013.04Positive
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.17M
Shares Outstanding99.02M
Trades Count2.93K
Dollar Volume44.07M
Avg. Volume2.73M
Avg. Weekly Volume2.62M
Avg. Monthly Volume1.37M
Avg. Quarterly Volume1.66M

Abeona Therapeutics Inc. (NASDAQ: ABEO) stock closed at 1.32 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 10.02M shares and market capitalization of 124.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Abeona Therapeutics Inc. CEO is .

The one-year performance of Abeona Therapeutics Inc. stock is -58.22%, while year-to-date (YTD) performance is -15.92%. ABEO stock has a five-year performance of -47.41%. Its 52-week range is between 0.9895 and 3.7899, which gives ABEO stock a 52-week price range ratio of 9.66%

Abeona Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 1.39, a price-to-sale (PS) ratio of 13.19, a price to cashflow ratio of 30.00, a PEG ratio of 2.32, a ROA of -31.79%, a ROC of -39.35% and a ROE of -44.28%. The company’s profit margin is -%, its EBITDA margin is -438.00%, and its revenue ttm is $10.00 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Abeona Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Abeona Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Abeona Therapeutics Inc. is Moderate Buy (1.88), with a target price of $4.67, which is +270.64% compared to the current price. The earnings rating for Abeona Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abeona Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Abeona Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.94, ATR14 : 0.11, CCI20 : -45.65, Chaikin Money Flow : -0.22, MACD : -0.09, Money Flow Index : 59.11, ROC : -10.20, RSI : 38.22, STOCH (14,3) : 42.11, STOCH RSI : 0.89, UO : 44.64, Williams %R : -57.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abeona Therapeutics Inc. in the last 12-months were: Edward G. Carr (Sold 55 445 shares of value $100 712 ), Michael Amoroso (Sold 45 409 shares of value $84 919 ), Paul E. Mann (Option Excercise at a value of $58 324), Paul E. Mann (Sold 225 797 shares of value $477 358 ), Todd Wider (Option Excercise at a value of $283 322), Todd Wider (Sold 624 815 shares of value $1 413 209 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (50.00 %)
4 (50.00 %)
4 (57.14 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
0 (0.00 %)
Hold
3 (37.50 %)
3 (37.50 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.88
Moderate Buy
1.88
Moderate Buy
1.86

Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-50X for the treatment of retinal diseases.

CEO:

Telephone: +1 646 813-4701

Address: 1330 Avenue of the Americas, New York 10019, NY, US

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

News

Stocktwits